Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.46 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309062 | 0.99 | TGM2 (0.53) | POLGTGM2PNPFUT5P2RY6 | |
| SCHEMBL14659959 | 0.92 | NT5E (0.51) | POLGTGM2PNPFUT5P2RY6 | |
| Triphosphate SCHEMBL28238456 | 0.91 | PNP (0.49) | POLGTGM2PNPFUT5P2RY6 | |
| SCHEMBL1743434 | 0.90 | NT5E (0.51) | TGM2FUT5P2RY6P2RY2P2RY4 | |
| SCHEMBL4410921 | 0.89 | TGM2 (0.55) | POLGTGM2PNPFUT5P2RY6 | |
| SCHEMBL30697339 | 0.88 | TGM2 (0.53) | POLGTGM2PNPFUT5P2RY6 | |
| SCHEMBL8435629 | 0.88 | POLG (0.51) | POLGTGM2PNPFUT5P2RY6 | |
| SCHEMBL4381958 | 0.88 | POLG (0.53) | POLGTGM2PNPFUT5P2RY6 | |
| SCHEMBL8438356 | 0.88 | POLG (0.53) | POLGTGM2PNPFUT5P2RY6 | |
| SCHEMBL30603197 | 0.87 | TGM2 (0.54) | POLGTGM2PNPFUT5P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136711-A1 | SEMENOGELIN NEUTRALIZING ANTIBODY AND EPITOPE AND APPLICATION THEREOF | SHANGHAI BIOTROY BIOTECHNIQUE CO., LTD (CN) | 2025-05-01 | — | — | US | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-11421038-B2 | RNA-coded antibody | CUREVAC AG (DE) | 2022-08-23 | — | — | US | claimed |
| EP-2083851-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | Curevac GmbH (DE) | 2009-08-05 | — | — | EP | claimed |
| WO-2008052770-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2008-05-08 | — | — | WO | claimed |
| US-5902793-A | ADMINISTERING TO MAMMAL GAMMA-MONOALKYL- OR GAMMA-ALKENYL-NUCLEOSIDE OR DEOXYNUCLEOSIDE TRIPHOSPHATE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-05-11 | — | — | US | claimed |
| WO-2026107144-A1 | RNA SEQUENCE FOR EXPRESSING PROTEIN IN CARDIOMYOCYTES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122070365-A | Systems and compositions comprising highly active trans-amplified replicase | 百欧恩泰欧洲股份公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260130981-A1 | INFLUENZA VIRUS VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-14 | — | — | US | disclosed |
| US-12618060-B2 | Nucleic acid molecules | CureVac SE (DE) | 2026-05-05 | — | — | US | disclosed |
| US-12606822-B2 | Synthetic modified RNA and uses thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260102470-A1 | IMMUNOGENIC PEPTIDES SPECIFIC TO BCMA AND TACI ANTIGENS FOR TREATMENT OF CANCER | DANA FARBER CANCER INST INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12599560-B2 | Lipids and lipid nanoparticle formulations | LONGUIDE BIOPHARMA CORPORATION (CN) | 2026-04-14 | — | — | US | disclosed |
| WO-2017023803-A1 | MODIFIED CELLS AND METHODS OF THERAPY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2015188933-A1 | METHODS AND MEANS FOR ENHANCING RNA PRODUCTION | CUREVAC AG (DE) | 2015-12-17 | — | — | WO | disclosed |
| US-20070281336-A1 | Kits and methods for generating 5' capped RNA | EPICENTRE TECHNOLOGIES (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1720556-A2 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005084192-A2 | NOVEL 2’-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-5902793-A | ADMINISTERING TO MAMMAL GAMMA-MONOALKYL- OR GAMMA-ALKENYL-NUCLEOSIDE OR DEOXYNUCLEOSIDE TRIPHOSPHATE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-05-11 | — | — | US | disclosed |
| US-5639653-A | ADMINISTERING MONOALKYL- OR ALKENYL-PYROPHOSPHATE TO MAMMAL TO STIMULATE LYMPHOCYTE CELL GROWTH AND ENHANCE IMMUNE RESPONSE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA UNIVERSTIY (US) | 1997-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599560-B2 | Lipids and lipid nanoparticle formulations | NPC1, NPC1L1, NSUN3 | POLG 1663/4885TGM2 4090/4885PNP 2511/4885 |
| US-12618060-B2 | Nucleic acid molecules | TP53, MICA, TAP1 | POLG 565/4885TGM2 1992/4885PNP 2557/4885 |
| US-20260130981-A1 | INFLUENZA VIRUS VACCINES | HLA-B, ADA, HLA-A | POLG 1787/4885TGM2 4380/4885PNP 347/4885 |
| US-20260102470-A1 | IMMUNOGENIC PEPTIDES SPECIFIC TO BCMA AND TACI ANTIGENS FOR TREATMENT OF CANCER | MICA, TAP1, CD74 | POLG 4092/4885TGM2 2163/4885PNP 4080/4885 |
| US-12606822-B2 | Synthetic modified RNA and uses thereof | CES1, MAT1A, CPS1 | POLG 2068/4885TGM2 1105/4885PNP 495/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | POLG 1198/4885TGM2 2809/4885PNP 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.